



11-30-05

TTW
CASE 4-31617B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 704617659 US
Express Mail Label Number

November 29, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1635

LIAU ET AL.

APPLICATION NO: 10/619,344

FILED: JULY 14, 2003

FOR: INTRODUCTION OF BLOOD VESSEL FORMATION THROUGH
ADMINISTRATION OF POLYNUCLEOTIDES ENCODING
SPHINGOSINE KINASES

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement of November 15, 2005, Applicant elects the claims of Group 2, claims 2-14, 23-28 and 33-39, drawn to methods expressing protein, inducing blood vessel formation in an animal by administering a polynucleotide encoding sphingosine kinase. This election is made without traverse.

Regarding the species of angiogenic factors listed in claims 4 and 35, Applicants select FGF as the species of angiogenic factor.

The due date for response to this Restriction Requirement is December 15, 2005. Accordingly, this election is timely made.

Respectfully submitted,


John T. Prince
Attorney for Applicants
Reg. No. 43,019

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346

Date: November 29, 2005